FGSKX
Price
$49.27
Change
+$0.05 (+0.10%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

FGSKX vs RPTIX

Header iconFGSKX vs RPTIX Comparison
Open Charts FGSKX vs RPTIXBanner chart's image
Federated Hermes MDT Mid Cap Growth R6
Price$49.27
Change+$0.05 (+0.10%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FGSKX vs RPTIX Comparison Chart
Loading...
VS
FGSKX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGSKX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. FGSKX (1.69B). RPTIX pays higher dividends than FGSKX: RPTIX (0.18) vs FGSKX (0.00). FGSKX was incepted earlier than RPTIX: FGSKX (18 years) vs RPTIX (9 years). FGSKX is a more actively managed with annual turnover of: 142.00 vs. RPTIX (21.70). FGSKX has a lower initial minimum investment than RPTIX: FGSKX (0) vs RPTIX (500000). FGSKX annual gain was more profitable for investors over the last year : 36.52 vs. RPTIX (14.81). FGSKX return over 5 years is better than : 26.33 vs. RPTIX (15.09).
FGSKXRPTIXFGSKX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence18 years9 years-
Gain YTD18.6949.127205%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.69B31.4B5%
Annual Yield % from dividends0.000.18-
Returns for 1 year36.5214.81247%
Returns for 3 years-11.67-13.5786%
Returns for 5 years26.3315.09175%
Returns for 10 years7.06N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp